Gavis to divest generic drugs for bacterial infections and UC to G&W
Executive Summary
Gavis Pharmaceuticals LLC will sell the rights and assets (including manufacturing technology) affiliated with generic doxycycline monohydrate capsules and generic mesalamine capsules to G&W Laboratories Inc. no later than ten days after closing its pending acquisition by Lupin Ltd.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice